Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Summary

To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .

Timeline

Start

2002-02-01

Primary completion

2007-01-01

Completion

2007-01-30

Publications

• Background List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. doi: 10.1056/NEJMoa041668.

Drugs

Indications